Lab
Lcsa LLC
Lcsa LLC was paid $1.06M by Medicaid between Nov 2018 and Dec 2024, across 48 billing codes. Its largest line is 87426, Infectious agent antigen detection, SARS-CoV-2 (COVID-19) — 12% of everything it billed.
33Billing provider infoLCSA LLC
QUEBRADILLAS, PR 00678
QUEBRADILLAS, PR 00678
33aNPI1467963900assigned 10/23/2017
33bProvider typeClinical Medical Laboratory
28Total paid$1.06M
24GClaims101,848
24DCodes billed48
24AFirst – last monthNov 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Puerto Rico
Rank by total paid#118 of 777
Median peer was paid$278K
This provider vs. median3.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 714 | $3K | |
| 2019 | 7,000 | $50K | |
| 2020 | 10,653 | $97K | |
| 2021 | 19,900 | $242K | |
| 2022 | 20,285 | $265K | |
| 2023 | 18,131 | $169K | |
| 2024incomplete | 25,165 | $236K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 12% | 3,141 | 2,737 | $130K |
| 84443 | Thyroid stimulating hormone (TSH) | 12% | 8,411 | 7,400 | $126K |
| 80061 | Lipid panel | 9.6% | 8,313 | 7,333 | $102K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 9.2% | 3,716 | 3,247 | $97K |
| 80053 | Comprehensive metabolic panel | 8.3% | 9,374 | 8,200 | $88K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 7.7% | 11,786 | 10,191 | $82K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 7.6% | 3,384 | 2,977 | $81K |
| 83036 | Hemoglobin; glycosylated (A1C) | 5.5% | 6,604 | 5,831 | $59K |
| 36415 | Collection of venous blood by venipuncture | 3.2% | 15,738 | 12,652 | $34K |
| 82274 | 2.9% | 2,130 | 1,894 | $31K | |
| 81000 | 2.6% | 9,640 | 8,475 | $27K | |
| 82607 | 2.5% | 1,882 | 1,572 | $26K |
36 more codes
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.8% | 383 | $20K |
| 86328 | 1.8% | 785 | $19K | |
| 84439 | 1.7% | 2,003 | $18K | |
| 84153 | 1.6% | 1,059 | $17K | |
| 82043 | 1.6% | 3,009 | $17K | |
| 86738 | 1.2% | 980 | $13K | |
| 87276 | 1.0% | 849 | $11K | |
| 87275 | <1% | 849 | $11K | |
| 87088 | <1% | 896 | $7K | |
| 86701 | <1% | 666 | $6K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 804 | $6K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 159 | $5K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 655 | $5K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 135 | $4K |
| 87186 | <1% | 470 | $4K | |
| 84479 | <1% | 550 | $3K | |
| 84436 | <1% | 388 | $2K | |
| 82570 | <1% | 486 | $2K | |
| 85651 | <1% | 502 | $2K | |
| 86592 | <1% | 314 | $1K | |
| 82378 | <1% | 52 | $924.28 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 17 | $862.33 |
| 86038 | <1% | 73 | $832.56 | |
| 86769 | <1% | 31 | $785.92 | |
| 86140 | <1% | 160 | $619.14 | |
| 85027 | <1% | 90 | $496.45 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 42 | $461.73 |
| 85730 | <1% | 58 | $317.50 | |
| 80076 | <1% | 39 | $278.47 | |
| 85610 | <1% | 58 | $208.92 | |
| 80050 | General health panel | <1% | 12 | $118.34 |
| 82565 | <1% | 15 | $73.75 | |
| 84520 | <1% | 15 | $56.85 | |
| 84295 | <1% | 679 | $9.18 | |
| 3044F | 0% | 21 | $0.00 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 0% | 425 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialVELEZ, OMAYRA (MEDICAL TECHNOLOGIST -OWNER)
Parent organizationLCSA LLC
| Provider | Location | Paid |
|---|---|---|
| Laboratorio Clinico San Antonio | Quebradillas, PR | $61K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.